Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B
Ben Samelson-Jones, Associate Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Sustained long term safety and efficacy (up to 6 years) with AAV gene therapy using FIX-Padua for hemophilia B.”
Title: Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B
Authors: Benjamin J Samelson-Jones, John EJ Rasko, Jonathan Ducore, Catherine McGuinn, Lindsey A. George, Sylvia von Mackensen, Gianluca Borgonuovo, Delphine Agathon, Lynne Smith, Lisa J Wilcox, Francesca Biondo, Frank Plonski
Read the Full Article on Blood Advances
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 13:39Amr Saad: What Tips You Toward Cerebral Venous Thrombosis Over IIH?
-
Aug 14, 2026, 13:28Eduardo Medronha: DIPS as a Rescue Strategy in Budd–Chiari Syndrome
-
Aug 14, 2026, 13:18Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
-
Aug 14, 2026, 13:04Mohammed M. Aboudeif: Cerebral Venous Thrombosis – Think Early, Treat Decisively
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank